Is HRT Safe? What the Evidence Says in 2026

For many women, the word "HRT" still comes with a warning attached. That largely traces back to the Women's Health Initiative (WHI), a large set of US trials whose early results, published in 2002, reported increased risks of breast cancer, heart disease, stroke and blood clots in women taking hormone therapy. Prescriptions fell dramatically afterward, and boxed warnings were added to product labels.

In the years since, researchers have re-examined that data. An important nuance: the WHI participants were, on average, in their 60s and many years past menopause - older than most women who start HRT for symptoms today. Later analyses suggested that the balance of risks and benefits looks different for younger women who start treatment closer to menopause.

In November 2025, the FDA asked manufacturers to remove the boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products, and to add more age-specific context about starting therapy. On February 12, 2026 it approved the first six updated labels - including Prometrium (progesterone), Divigel (estradiol gel) and Estring (vaginal estradiol) - with other products following as their manufacturers' changes are reviewed. The agency pointed to evidence that HRT started within about 10 years of menopause, generally before age 60, has a more favorable balance of benefits and risks.

That matches the long-term findings of the Women's Health Initiative itself: a 2024 review of the trials in JAMA concluded that women who start hormone therapy in early menopause have lower absolute risks than women who start it later.

Two important caveats: the FDA did not remove the boxed warning about endometrial cancer for systemic estrogen-alone products (which is why women with a uterus are generally prescribed a progestogen alongside estrogen), and removing a boxed warning does not mean the risks disappeared. They remain part of the prescribing information and part of the conversation with your clinician.

The full story - the 2002 trial behind the box, the July 2025 panel, what the FDA kept and what the societies said - is in our guide to the HRT black box warning removal.

Hormone therapy is a real medication with real risks. The main ones clinicians weigh include:

• Blood clots (venous thromboembolism) - the risk is associated particularly with oral estrogen; transdermal routes (patch, gel) are thought to carry a lower clot risk, which is one reason route matters.
• Stroke - a small increased risk, especially with oral estrogen and in older women.
• Breast cancer - combined estrogen-plus-progestogen therapy has been associated with a small increase in risk with longer use; the picture differs for estrogen alone.
• Endometrial cancer - estrogen alone in a woman with a uterus raises this risk, which progestogen protects against.
• Gallbladder disease and common side effects such as breast tenderness, bloating or bleeding.

These risks are why an honest, complete medical intake matters so much - and why dosing and route are clinician decisions.

HRT is not suitable for everyone. Clinicians are generally cautious or will avoid systemic hormone therapy in women with a history of:

• Breast cancer or other estrogen-sensitive cancers
• Blood clots, stroke or heart attack
• Unexplained vaginal bleeding
• Active liver disease
• Certain clotting disorders

This list is not exhaustive. Some women in these groups may still be candidates for low-dose vaginal estrogen or non-hormonal treatments, but that is a decision for a specialist who knows your full history.

For appropriate candidates, HRT is the most effective treatment available for hot flashes and night sweats, and it can improve sleep disrupted by those symptoms. Vaginal estrogen is highly effective for dryness and related urinary symptoms. Systemic estrogen also helps prevent bone loss. Major professional bodies, including The Menopause Society, support hormone therapy as an appropriate option for many healthy women with bothersome symptoms who start it before age 60 or within 10 years of menopause - while emphasizing individualized decisions.

The safest path is a clinician who takes a full history, explains your personal risk, chooses the route and dose deliberately, and reviews your treatment over time. Licensed online services can do this well - compare how Winona, Gala and Midi Health handle it, or see our head-to-head of Winona vs Midi Health.

This article is general information, not medical advice. Only a licensed clinician can determine whether hormone therapy is appropriate for you.